Current conventional treatments for PD, primarily involving levodopa, are associated with "on-off" effects and significant medication complications. When patients experience reduced drug efficacy, clinical interventions typically include stereotactic targeting radiofrequency ablation (cell knife) and deep brain stimulation (DBS, or "brain pacemaker"). However, these treatments cannot reverse the disease course. To date, no curative therapy exists to alter or reverse the underlying disease progression. Some drug treatments may even exacerbate non-motor symptoms of PD.
Recent research has focused on cell transplantation to replace lost dopaminergic neurons, aiming to restore neurotransmission and protect remaining dopaminergic neurons. This approach holds promise for fundamentally treating or curing PD.
The use of induced pluripotent stem cells (iPSCs) has emerged as a key direction. iPSCs can self-replicate and directed differentiate into dopaminergic neurons. Achieving high-purity, large-scale, standardized production with strict quality control becomes the primary research focus.
|
iPSC-Derived Dopaminergic Progenitor Cells for the Treatment of PD
Through years of technological optimization and iteration, Nuwacell has developed a high-purity, universal iDAP product with the potential to provide a curative treatment for PD. |